Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free ANIX Stock Alerts

Anixa Biosciences (ANIX) Financials

Anixa Biosciences logo
$3.46 -0.24 (-6.49%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Anixa Biosciences

Annual Income Statements for Anixa Biosciences

This table shows Anixa Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025
Period end date 10/31/2014 10/31/2015 10/31/2016 10/31/2017 10/31/2018 10/31/2019 10/31/2020 10/31/2022 10/31/2023 10/31/2024 10/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.61 -1.38 -5.02 -7.02 -14 -12 -9.87 -14 -9.81 -13 -11
Consolidated Net Income / (Loss)		 -9.61 -1.38 -5.02 -5.01 -14 -12 -20 -14 -9.93 -13 -11
Net Income / (Loss) Continuing Operations		 -9.61 -1.38 -5.02 -5.01 -14 -12 -9.94 -14 -9.93 -13 -11
Total Pre-Tax Income 		-9.61 -1.38 -5.02 -5.01 -14 -12 -9.94 -14 -9.93 -13 -11
Total Operating Income		 -5.04 -0.94 -4.51 -6.08 -14 -12 -9.98 -14 -11 -14 -12
Total Gross Profit		 3.67 9.26 0.30 0.36 1.11 0.25 0.00 0.00 0.21 0.00 0.00
Total Revenue		 3.67 9.26 0.30 0.36 1.11 0.25 0.00 0.00 0.21 0.00 0.00
Operating Revenue		 3.67 9.26 0.30 0.36 1.11 0.25 0.00 0.00 0.21 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 8.71 10 4.81 6.44 15 12 9.98 14 11 14 12
Selling, General & Admin Expense		 6.41 5.51 2.71 4.41 6.91 5.66 5.60 7.17 6.29 7.44 6.63
Research & Development Expense		 - 0.71 1.56 1.60 6.81 5.47 4.38 6.70 4.77 6.40 5.07
Total Other Income / (Expense), net		 -4.56 -0.43 -0.51 1.07 0.05 0.07 0.03 0.10 1.08 1.13 0.67
Interest & Investment Income		 0.06 0.02 0.01 0.02 0.05 0.07 0.03 0.10 1.08 1.13 0.67
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - 0.00 -0.25 -0.17 -0.07 -0.18 -0.12 -0.14 -0.10
Basic Earnings per Share		 ($1.10) ($16.00) ($0.57) ($0.58) ($0.79) ($0.59) ($0.45) $0.45 ($0.32) ($0.39) ($0.34)
Weighted Average Basic Shares Outstanding		 8.71M 8.76M 8.74M 12.20M 17.62M 19.79M 22.23M 30.37K 30.98M 31.90M 32.45M
Diluted Earnings per Share		 ($1.10) ($16.00) ($0.57) ($0.58) ($0.79) ($0.59) ($0.45) $0.45 ($0.32) ($0.39) ($0.34)
Weighted Average Diluted Shares Outstanding		 8.71M 8.76M 8.74M 12.20M 17.62M 19.79M 22.23M 30.37K 30.98M 31.90M 32.45M
Weighted Average Basic & Diluted Shares Outstanding		 8.71M 8.76M 8.74M 12.20M 17.62M 19.79M 22.23M 30.92M 31.70M 32.20M 33.38M

Quarterly Income Statements for Anixa Biosciences

This table shows Anixa Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 1/31/2026 4/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.69 -3.26 -3.14 -3.28 -2.88 -3.18 -2.79 -2.26 -2.70 -2.57 -2.52
Consolidated Net Income / (Loss)		 -2.72 -3.29 -3.18 -3.32 -2.91 -3.21 -2.81 -2.28 -2.72 -2.59 -2.54
Net Income / (Loss) Continuing Operations		 -2.72 -3.29 -3.18 -3.32 -2.91 -3.21 -2.81 -2.28 -2.72 -2.59 -2.54
Total Pre-Tax Income 		-2.72 -3.29 -3.18 -3.32 -2.91 -3.21 -2.81 -2.28 -2.72 -2.59 -2.54
Total Operating Income		 -3.05 -3.61 -3.47 -3.59 -3.16 -3.39 -3.00 -2.44 -2.88 -2.72 -2.65
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Operating Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 3.05 3.61 3.47 3.59 3.16 3.39 3.00 2.44 2.88 2.72 2.65
Selling, General & Admin Expense		 1.44 2.26 1.82 1.67 1.69 1.83 1.68 1.38 1.73 1.61 1.39
Research & Development Expense		 1.62 1.35 1.65 1.93 1.48 1.55 1.32 1.06 1.14 1.10 1.26
Total Other Income / (Expense), net		 0.33 0.32 0.29 0.28 0.25 0.17 0.19 0.16 0.15 0.13 0.11
Interest & Investment Income		 0.33 0.32 0.29 0.28 0.25 0.17 0.19 0.16 0.15 0.13 0.11
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.03 -0.04 -0.04 -0.04 -0.03 -0.03 -0.02 -0.02 -0.03 -0.02 -0.02
Basic Earnings per Share		 ($0.25) ($0.10) ($0.10) ($0.10) ($0.09) ($0.10) ($0.09) ($0.07) ($0.08) ($0.08) ($0.07)
Weighted Average Basic Shares Outstanding		 30.98M 31.45M 31.91M 32.05M 31.90M 32.20M 32.20M 32.48M 32.45M 33.24M 33.59M
Diluted Earnings per Share		 ($0.25) ($0.10) ($0.10) ($0.10) ($0.09) ($0.10) ($0.09) ($0.07) ($0.08) ($0.08) ($0.07)
Weighted Average Diluted Shares Outstanding		 30.98M 31.45M 31.91M 32.05M 31.90M 32.20M 32.20M 32.48M 32.45M 33.24M 33.59M
Weighted Average Basic & Diluted Shares Outstanding		 31.70M 31.90M 32.01M 32.18M 32.20M 32.20M 32.21M 32.92M 33.38M 33.53M 34.02M

Annual Cash Flow Statements for Anixa Biosciences

This table details how cash moves in and out of Anixa Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025
Period end date 10/31/2014 10/31/2015 10/31/2016 10/31/2017 10/31/2018 10/31/2019 10/31/2020 10/31/2022 10/31/2023 10/31/2024 10/31/2025
Net Change in Cash & Equivalents		 2.46 1.01 -1.88 0.85 -0.28 0.44 2.93 -17 -11 0.36 -0.03
Net Cash From Operating Activities		 -2.38 1.36 -3.38 -3.80 -4.27 -4.74 -6.18 -6.49 -6.21 -7.34 -7.17
Net Cash From Continuing Operating Activities		 -2.38 1.36 -3.38 -3.80 -4.27 -4.74 -6.18 -6.49 -6.21 -7.34 -7.17
Net Income / (Loss) Continuing Operations		 -9.61 -1.38 -5.02 -5.01 -14 -12 -10 -14 -9.93 -13 -11
Consolidated Net Income / (Loss)		 -9.61 -1.38 -5.02 -5.01 -14 -12 -10 -14 -9.93 -13 -11
Amortization Expense		 0.95 0.33 0.33 0.33 0.33 0.42 0.05 0.04 0.05 0.04 -0.11
Non-Cash Adjustments To Reconcile Net Income		 7.62 2.94 1.22 0.44 9.56 6.13 4.23 6.71 4.69 4.76 3.78
Changes in Operating Assets and Liabilities, net		 -1.34 -0.53 0.05 0.41 0.07 0.48 -0.41 0.52 -1.01 0.57 0.18
Net Cash From Investing Activities		 -2.51 0.05 1.50 -2.74 1.46 -0.53 -0.31 -11 -5.60 4.28 4.87
Net Cash From Continuing Investing Activities		 -2.51 0.05 1.50 -2.74 1.46 -0.53 -0.31 -11 -5.60 4.28 4.87
Purchase of Investments		 -5.20 -2.90 -1.90 -5.50 -4.25 -3.85 -5.01 -22 -44 -64 -44
Sale and/or Maturity of Investments		 2.70 3.00 3.55 2.75 5.75 3.50 4.72 12 39 68 49
Net Cash From Financing Activities		 7.35 -0.40 -0.00 7.38 2.53 5.70 9.41 0.45 0.37 3.42 2.28
Net Cash From Continuing Financing Activities		 7.35 -0.40 -0.00 7.38 2.53 5.70 9.41 0.45 0.37 3.42 2.28
Issuance of Common Equity		 3.67 - 0.00 6.67 2.47 5.57 9.28 0.01 0.01 2.97 2.39
Other Financing Activities, net		 0.38 0.04 -0.00 1.21 0.06 0.14 0.12 0.44 0.35 0.45 -0.11

Quarterly Cash Flow Statements for Anixa Biosciences

This table details how cash moves in and out of Anixa Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 1/31/2026 4/30/2026
Net Change in Cash & Equivalents		 -2.28 0.08 -0.00 0.23 0.05 -0.22 0.86 -0.42 -0.25 0.30 -0.07
Net Cash From Operating Activities		 -1.97 -2.31 -1.46 -2.64 -0.93 -2.90 -1.50 -1.51 -1.26 -2.61 -1.74
Net Cash From Continuing Operating Activities		 -1.97 -2.31 -1.46 -2.64 -0.93 -2.90 -1.50 -1.51 -1.26 -2.61 -1.74
Net Income / (Loss) Continuing Operations		 -2.72 -3.29 -3.18 -3.32 -2.91 -3.21 -2.81 -2.28 -2.72 -2.59 -2.54
Consolidated Net Income / (Loss)		 -2.72 -3.29 -3.18 -3.32 -2.91 -3.21 -2.81 -2.28 -2.72 -2.59 -2.54
Amortization Expense		 0.01 0.01 0.01 0.00 0.01 -0.24 0.18 -0.01 -0.04 0.06 0.03
Non-Cash Adjustments To Reconcile Net Income		 1.18 1.26 1.26 1.28 0.96 1.06 0.99 0.86 0.88 0.80 0.67
Changes in Operating Assets and Liabilities, net		 -0.44 -0.29 0.45 -0.61 1.02 -0.50 0.14 -0.08 0.63 -0.88 0.10
Net Cash From Investing Activities		 -0.59 0.13 0.56 2.72 0.87 2.70 2.34 -0.83 0.65 1.23 0.42
Net Cash From Continuing Investing Activities		 -0.59 0.13 0.56 2.72 0.87 2.70 2.34 -0.83 0.65 1.23 0.42
Purchase of Investments		 -17 -20 -15 -13 -16 -13 -12 -12 -7.66 -13 -12
Sale and/or Maturity of Investments		 16 20 15 15 17 16 14 11 8.31 14 13
Net Cash From Financing Activities		 0.28 2.26 0.90 0.15 0.11 -0.02 0.02 1.93 0.35 1.69 1.25
Net Cash From Continuing Financing Activities		 0.28 2.26 0.90 0.15 0.11 -0.02 0.02 1.93 0.35 1.69 1.25
Other Financing Activities, net		 0.27 0.07 0.06 0.19 0.13 -0.02 0.02 0.00 -0.11 1.69 -1.63

Annual Balance Sheets for Anixa Biosciences

This table presents Anixa Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025
Period end date 10/31/2014 10/31/2015 10/31/2016 10/31/2017 10/31/2018 10/31/2019 10/31/2020 10/31/2022 10/31/2023 10/31/2024 10/31/2025
Total Assets		 9.06 9.34 5.63 8.81 6.45 6.29 9.45 30 26 22 16
Total Current Assets		 6.32 6.90 3.40 7.01 5.54 6.09 9.37 30 25 21 16
Cash & Equivalents		 3.36 4.37 2.49 3.34 3.06 3.49 6.42 12 0.92 1.27 1.24
Short-Term Investments		 2.50 2.40 0.75 3.50 2.00 2.35 2.64 17 23 19 14
Accounts Receivable		 0.40 - - - 0.31 0.07 - 0.05 0.27 0.17 0.00
Prepaid Expenses		 0.06 0.13 0.16 0.17 0.18 0.18 0.31 0.47 1.24 1.27 0.71
Plant, Property, & Equipment, net		 0.01 0.04 0.16 0.05 0.07 0.20 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 2.72 2.40 2.07 1.75 0.84 0.00 0.08 0.21 0.17 0.23 0.19
Other Noncurrent Operating Assets		 - - - - - 0.00 0.08 0.21 0.17 0.23 0.19
Total Liabilities & Shareholders' Equity		 9.06 9.34 5.63 8.81 6.45 6.29 9.45 30 26 22 16
Total Liabilities		 5.05 4.28 4.64 0.89 1.27 1.48 1.19 2.21 2.15 2.70 2.13
Total Current Liabilities		 1.81 0.59 0.47 0.89 1.27 1.48 1.19 2.04 2.03 2.50 1.97
Accounts Payable		 1.25 0.38 0.37 0.48 0.58 0.59 0.23 0.27 0.21 0.53 0.17
Accrued Expenses		 - - 0.10 0.41 0.68 0.90 0.90 1.73 1.77 1.95 1.76
Other Current Liabilities		 0.56 0.21 - - - 0.00 0.06 0.05 0.05 0.03 0.04
Total Noncurrent Liabilities		 3.24 3.69 4.17 0.00 0.00 0.00 0.00 0.18 0.12 0.20 0.16
Other Noncurrent Operating Liabilities		 3.24 3.69 4.17 - - - 0.00 0.18 0.12 0.20 0.16
Commitments & Contingencies		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 4.01 5.05 0.99 7.92 5.18 4.81 8.26 28 23 19 14
Total Preferred & Common Equity		 4.01 5.05 0.99 7.92 5.43 5.24 8.76 29 24 20 15
Preferred Stock		 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 4.00 5.04 0.97 7.92 5.43 5.24 8.76 29 24 20 15
Common Stock		 149 151 152 164 176 187 201 247 253 261 267
Retained Earnings		 -145 -146 -151 -156 -170 -182 -192 -218 -228 -241 -252
Other Equity Adjustments		 - - - 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Noncontrolling Interest		 - - - 0.00 -0.25 -0.42 -0.50 -0.85 -0.97 -1.11 -1.21

Quarterly Balance Sheets for Anixa Biosciences

This table presents Anixa Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 7/31/2023 1/31/2024 4/30/2024 7/31/2024 1/31/2025 4/30/2025 7/31/2025 1/31/2026 4/30/2026
Total Assets		 27 25 24 23 19 17 18 15 15
Total Current Assets		 26 25 24 23 19 17 17 15 15
Cash & Equivalents		 3.20 1.00 1.00 1.23 1.05 1.91 1.50 1.55 1.48
Short-Term Investments		 22 23 22 20 16 14 15 13 12
Accounts Receivable		 0.33 0.39 0.22 0.41 0.00 0.00 0.00 - 0.06
Prepaid Expenses		 0.53 1.03 0.76 1.52 1.43 1.17 1.42 0.85 0.95
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.18 0.15 0.14 0.24 0.22 0.21 0.20 0.18 0.17
Other Noncurrent Operating Assets		 0.18 0.15 0.14 0.24 0.22 0.21 0.20 0.18 0.17
Total Liabilities & Shareholders' Equity		 27 25 24 23 19 17 18 15 15
Total Liabilities		 1.99 1.77 1.77 2.22 2.19 2.07 2.24 1.39 1.64
Total Current Liabilities		 1.86 1.66 1.68 2.00 2.00 1.89 2.07 1.24 1.50
Accounts Payable		 0.09 0.36 0.22 0.30 0.60 0.28 0.28 0.15 0.25
Accrued Expenses		 1.71 1.24 1.41 1.68 1.36 1.57 1.75 1.05 1.21
Other Current Liabilities		 0.05 0.05 0.06 0.02 0.04 0.04 0.04 0.04 0.04
Total Noncurrent Liabilities		 0.14 0.11 0.09 0.21 0.19 0.18 0.17 0.15 0.14
Other Noncurrent Operating Liabilities		 0.14 0.11 0.09 0.21 0.19 0.18 0.17 0.15 0.14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 25 24 23 21 17 15 15 14 13
Total Preferred & Common Equity		 26 25 24 22 18 16 17 15 14
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 26 25 24 22 18 16 17 15 14
Common Stock		 251 256 258 260 262 263 266 269 271
Retained Earnings		 -226 -231 -235 -238 -244 -247 -249 -254 -257
Other Equity Adjustments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Noncontrolling Interest		 -0.94 -1.00 -1.04 -1.08 -1.14 -1.16 -1.18 -1.23 -1.25

Annual Metrics And Ratios for Anixa Biosciences

This table displays calculated financial ratios and metrics derived from Anixa Biosciences' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025
Period end date 10/31/2014 10/31/2015 10/31/2016 10/31/2017 10/31/2018 10/31/2019 10/31/2020 10/31/2022 10/31/2023 10/31/2024 10/31/2025
DEI Shares Outstanding		 182,682,922.00 182,682,922.00 182,682,922.00 182,682,922.00 18,696,146.00 20,207,261.00 23,789,386.00 30,661,692.00 31,070,022.00 32,179,492.00 32,916,915.00
DEI Adjusted Shares Outstanding		 182,682,922.00 182,682,922.00 182,682,922.00 182,682,922.00 18,696,146.00 20,207,261.00 23,789,386.00 30,661,692.00 31,070,022.00 32,179,492.00 32,916,915.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.05 -0.01 -0.03 -0.04 -0.75 -0.58 -0.41 -0.44 -0.32 -0.39 -0.33
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 843.12% 152.36% -96.76% 20.83% 206.90% -77.53% -100.00% 0.00% 0.00% -100.00% 0.00%
EBITDA Growth		 37.78% 87.23% -583.81% -37.51% -144.35% 18.08% 13.44% 0.00% 20.73% -25.80% 14.40%
EBIT Growth		 33.93% 83.42% -377.27% -34.74% -135.19% 16.79% 16.08% 0.00% 20.64% -25.61% 15.40%
NOPAT Growth		 36.29% 81.27% -377.27% -34.74% -135.19% 16.79% 16.08% 0.00% 20.64% -25.61% 15.40%
Net Income Growth		 4.70% 85.64% -263.76% 0.15% -184.35% 17.02% -70.16% 0.00% 27.89% -27.88% 13.15%
EPS Growth		 -2,100.00% -1,354.55% 96.44% -1.75% -36.21% 25.32% 23.73% 0.00% -171.11% -21.88% 12.82%
Operating Cash Flow Growth		 25.34% 157.30% -348.04% -12.27% -12.56% -10.95% -30.25% 0.00% 4.36% -18.14% 2.21%
Free Cash Flow Firm Growth		 -3.22% 82.46% -228.71% -189.47% -19.23% 20.78% -0.77% 0.00% 0.00% -4.55% 12.24%
Invested Capital Growth		 35.43% 7.35% -31.20% 148.14% -88.23% -906.99% 22.98% 0.00% 68.19% -119.03% -18.15%
Revenue Q/Q Growth		 36.78% -12.94% 200.00% -35.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -9.26% 35.93% 6.69% -16.82% -35.78% 21.92% -1.17% 0.00% 4.85% -0.84% 1.97%
EBIT Q/Q Growth		 -8.47% 29.06% 5.54% -15.70% -34.56% 21.62% -1.15% 0.00% 4.82% -0.82% 2.39%
NOPAT Q/Q Growth		 4.01% 29.06% 5.54% -15.70% -34.56% 21.62% -1.15% 0.00% 4.82% -0.82% 2.39%
Net Income Q/Q Growth		 -2.42% 57.44% 4.65% -17.28% -33.90% 21.73% -101.87% 0.00% 7.52% -1.54% 1.70%
EPS Q/Q Growth		 0.00% -1,697.75% 96.58% 6.45% -41.07% 25.32% 2.17% 0.00% 0.00% 29.09% 2.86%
Operating Cash Flow Q/Q Growth		 7.12% -24.39% 3.40% -1.51% -7.06% -7.14% -1.26% 0.00% -6.45% 12.44% -4.79%
Free Cash Flow Firm Q/Q Growth		 -362.80% 89.80% 1.96% -3.79% -32.00% 17.61% -2.10% 100.00% -10.31% 13.14% -2.24%
Invested Capital Q/Q Growth		 78.08% -9.75% -0.89% -22.78% -84.50% 6.24% 14.76% -96.43% 50.16% -1,818.52% -98.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -129.55% -6.56% -1,383.46% -1,574.36% -1,253.51% -4,569.48% 0.00% 0.00% -5,221.43% 0.00% 0.00%
Operating Margin		 -137.54% -10.21% -1,503.00% -1,676.02% -1,284.41% -4,756.00% 0.00% 0.00% -5,243.33% 0.00% 0.00%
EBIT Margin		 -155.42% -10.21% -1,503.00% -1,676.02% -1,284.41% -4,756.00% 0.00% 0.00% -5,243.33% 0.00% 0.00%
Profit (Net Income) Margin		 -261.94% -14.90% -1,672.14% -1,381.79% -1,280.28% -4,727.46% 0.00% 0.00% -4,728.57% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 202.23% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 168.54% 145.97% 111.25% 82.44% 99.68% 99.40% 99.66% 99.25% 90.18% 91.81% 94.25%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -1,651.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -1,580.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 1,434.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -2,788.56% -30.43% -166.08% -112.43% -217.35% -236.47% -307.58% -48.83% -38.51% -60.10% -67.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -700.23% -1,493.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -78.65% -10.27% -60.27% -84.15% -187.26% -186.62% 0.00% 0.00% -39.37% 0.00% 0.00%
Return on Assets (ROA)		 -132.55% -15.00% -67.05% -69.37% -186.66% -185.50% 0.00% 0.00% -35.51% 0.00% 0.00%
Return on Common Equity (ROCE)		 -2,731.90% -30.34% -165.31% -112.25% -221.51% -252.43% -329.22% -50.30% -39.86% -63.05% -71.91%
Return on Equity Simple (ROE_SIMPLE)		 -239.58% -27.29% -508.01% -63.22% -262.07% -225.75% -229.54% -47.41% -40.80% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.53 -0.66 -3.16 -4.25 -10 -8.32 -6.98 -9.71 -7.71 -9.68 -8.19
NOPAT Margin		 -96.28% -7.15% -1,052.10% -1,173.22% -899.09% -3,329.20% 0.00% 0.00% -3,670.33% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -224.68% -11.36% -37.17% -15.01% -71.30% -64.16% -176.20% -13.67% -8.30% -13.78% -16.17%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -32.98% -51.26% -58.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 174.76% 59.58% 903.28% 1,216.74% 621.29% 2,265.13% 0.00% 0.00% 2,995.71% 0.00% 0.00%
R&D to Revenue		 0.00% 7.69% 518.82% 440.70% 612.41% 2,189.37% 0.00% 0.00% 2,270.95% 0.00% 0.00%
Operating Expenses to Revenue		 237.54% 110.21% 1,603.00% 1,776.02% 1,384.41% 4,856.00% 0.00% 0.00% 5,343.33% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.70 -0.94 -4.51 -6.08 -14 -12 -9.98 -14 -11 -14 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.75 -0.61 -4.15 -5.71 -14 -11 -9.89 -14 -11 -14 -12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 13.93 14.94 5.59 5.91 4.03 5.63 8.97
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 16.47 14.94 5.59 5.91 4.03 5.63 8.97
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 68.06 312.81 0.00 0.00 467.53 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 552.07 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 63.29 287.75 0.00 0.00 349.39 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -7.85 -1.39 -1.66 -1.13 -0.91 -1.09 -1.14 -1.05 -1.04 -1.04 -1.07
Leverage Ratio		 21.04 2.03 2.48 1.62 1.16 1.27 1.20 1.08 1.08 1.11 1.15
Compound Leverage Factor		 35.46 2.96 2.76 1.34 1.16 1.27 1.20 1.07 0.98 1.02 1.08
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.35% 0.28% 1.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% -4.85% -8.79% -6.01% -3.00% -4.13% -5.88% -8.68%
Common Equity to Total Capital		 99.65% 99.72% 98.58% 100.00% 104.85% 108.79% 106.01% 103.00% 104.13% 105.88% 108.68%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 -7.38 -14.08 -6.12 36.13 14.55 8.32 15.02
Noncontrolling Interest Sharing Ratio		 2.03% 0.31% 0.46% 0.16% -1.92% -6.75% -7.04% -3.00% -3.52% -4.91% -7.07%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.49 11.61 7.25 7.89 4.38 4.11 7.88 14.83 12.50 8.54 8.08
Quick Ratio		 3.46 11.40 6.91 7.69 4.24 3.99 7.62 14.60 11.89 8.04 7.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.55 -0.80 -2.62 -7.59 -9.05 -7.17 -7.22 0.00 -8.72 -9.12 -8.00
Operating Cash Flow to CapEx		 -35,596.36% 2,488.99% -2,308.00% 0.00% -11,127.49% -2,702.33% -39,108.80% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -1.15 -1.76 -5.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -0.60 3.02 -6.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -0.60 2.90 -6.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.51 1.01 0.04 0.05 0.15 0.04 0.00 0.00 0.01 0.00 0.00
Accounts Receivable Turnover		 12.76 0.00 0.00 0.00 0.00 1.34 0.00 0.00 1.33 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 362.13 334.53 3.00 3.46 17.75 1.83 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 28.61 0.00 0.00 0.00 0.00 272.67 0.00 0.00 274.62 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 28.61 0.00 0.00 0.00 0.00 272.67 0.00 0.00 274.62 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.85 -1.72 -2.25 1.08 0.13 -1.03 -0.79 -1.49 -0.47 -1.04 -1.22
Invested Capital Turnover		 -1.55 -5.19 -0.15 -0.62 1.84 -0.55 0.00 0.00 -0.21 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.02 0.14 -0.54 3.33 -0.96 -1.16 0.24 0.00 1.01 -0.56 -0.19
Enterprise Value (EV)		 0.00 0.00 0.00 0.00 70 72 39 141 73 92 120
Market Capitalization		 0.00 0.00 0.00 0.00 76 78 49 172 98 113 136
Book Value per Share		 $0.46 $0.58 $0.11 $0.65 $0.29 $0.26 $0.37 $0.95 $0.78 $0.62 $0.46
Tangible Book Value per Share		 $0.15 $0.30 ($0.13) $0.51 $0.25 $0.26 $0.37 $0.95 $0.78 $0.62 $0.46
Total Capital		 4.01 5.05 0.99 7.92 5.18 4.81 8.26 28 23 19 14
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -5.86 -6.77 -3.24 -6.84 -5.06 -5.84 -9.06 -30 -24 -20 -15
Capital Expenditures (CapEx)		 0.01 0.05 0.15 -0.01 0.04 0.18 0.02 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.35 -0.47 -0.31 -0.71 -0.78 -1.23 -0.88 -1.52 -0.52 -1.06 -1.25
Debt-free Net Working Capital (DFNWC)		 4.51 6.30 2.93 6.12 4.27 4.61 8.18 28 23 19 14
Net Working Capital (NWC)		 4.51 6.30 2.93 6.12 4.27 4.61 8.18 28 23 19 14
Net Nonoperating Expense (NNE)		 6.08 0.72 1.86 0.76 4.24 3.50 13 4.06 2.22 3.02 2.84
Net Nonoperating Obligations (NNO)		 -5.86 -6.77 -3.24 -6.84 -5.06 -5.84 -9.06 -30 -24 -20 -15
Total Depreciation and Amortization (D&A)		 0.95 0.34 0.36 0.37 0.34 0.47 0.09 0.04 0.05 0.04 -0.11
Debt-free, Cash-free Net Working Capital to Revenue		 -36.78% -5.05% -102.23% -197.22% -70.35% -491.93% 0.00% 0.00% -245.71% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 123.04% 68.09% 977.21% 1,689.50% 384.11% 1,844.72% 0.00% 0.00% 11,108.57% 0.00% 0.00%
Net Working Capital to Revenue		 123.04% 68.09% 977.21% 1,689.50% 384.11% 1,844.72% 0.00% 0.00% 11,108.57% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.04) ($0.16) ($0.57) ($0.58) ($0.79) ($0.59) ($0.45) $0.00 $0.32 ($0.39) ($0.34)
Adjusted Weighted Average Basic Shares Outstanding		 219.71M 8.72M 8.75M 16.61M 19.29M 20.82M 26.08M 0.00 30.98K 31.90M 32.45M
Adjusted Diluted Earnings per Share		 ($0.04) ($0.16) ($0.57) ($0.58) ($0.79) ($0.59) ($0.45) $0.00 $0.32 ($0.39) ($0.34)
Adjusted Weighted Average Diluted Shares Outstanding		 219.71M 8.72M 8.75M 16.61M 19.29M 20.82M 26.08M 0.00 30.98K 31.90M 32.45M
Adjusted Basic & Diluted Earnings per Share		 ($0.04) ($0.16) ($0.57) ($0.58) ($0.79) ($0.59) ($0.45) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 217.77M 8.76M 8.74M 12.20M 17.62M 19.79M 22.23M 0.00 31.70M 32.20M 33.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.53 -0.66 -3.16 -4.25 -9.59 -8.03 -6.98 -9.71 -7.71 -9.68 -8.19
Normalized NOPAT Margin		 -96.28% -7.15% -1,052.10% -1,173.22% -862.41% -3,211.95% 0.00% 0.00% -3,670.33% 0.00% 0.00%
Pre Tax Income Margin		 -261.94% -14.90% -1,672.14% -1,381.79% -1,280.28% -4,727.46% 0.00% 0.00% -4,728.57% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1.44 -2.09 -8.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -0.89 -1.46 -6.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -1.44 -2.21 -8.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -0.89 -1.58 -6.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -32.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Anixa Biosciences

This table displays calculated financial ratios and metrics derived from Anixa Biosciences' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 1/31/2026 4/30/2026
DEI Shares Outstanding		 31,070,022.00 31,070,022.00 31,899,800.00 32,006,460.00 32,179,492.00 32,196,862.00 32,196,862.00 32,211,092.00 32,916,915.00 33,376,690.00 33,527,858.00
DEI Adjusted Shares Outstanding		 31,070,022.00 31,070,022.00 31,899,800.00 32,006,460.00 32,179,492.00 32,196,862.00 32,196,862.00 32,211,092.00 32,916,915.00 33,376,690.00 33,527,858.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.09 -0.10 -0.10 -0.10 -0.09 -0.10 -0.09 -0.07 -0.08 -0.08 -0.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 15.54% -41.30% -35.60% -26.69% -3.78% -0.92% 18.35% 31.99% 7.51% 26.73% 7.37%
EBIT Growth		 15.46% -41.20% -35.43% -26.30% -3.67% 6.18% 13.38% 32.18% 9.07% 19.79% 11.85%
NOPAT Growth		 15.46% -41.20% -35.43% -26.30% -3.67% 6.18% 13.38% 32.18% 9.07% 19.79% 11.85%
Net Income Growth		 22.90% -39.76% -37.84% -30.10% -7.06% 2.34% 11.54% 31.22% 6.56% 19.55% 9.85%
EPS Growth		 0.00% -225.00% -42.86% -25.00% 64.00% 0.00% 10.00% 30.00% 11.11% 20.00% 22.22%
Operating Cash Flow Growth		 -23.60% -16.15% -80.42% -82.91% 52.92% -25.77% -3.23% 42.83% -35.38% 10.12% -15.84%
Free Cash Flow Firm Growth		 0.00% -36.51% -82.23% -89.54% 47.58% 35.23% 26.94% 66.53% -10.54% -3.21% -0.62%
Invested Capital Growth		 68.19% 75.44% 38.10% 94.31% -119.03% -179.38% -5.02% -1,044.44% -18.15% 34.32% 33.14%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -7.27% -18.33% 3.92% -3.88% 12.12% -15.06% 22.27% 13.47% -19.50% 8.84% 1.73%
EBIT Q/Q Growth		 -7.28% -18.29% 3.93% -3.61% 11.94% -7.05% 11.31% 18.88% -18.06% 5.56% 2.54%
NOPAT Q/Q Growth		 -7.28% -18.29% 3.93% -3.61% 11.94% -7.05% 11.31% 18.88% -18.06% 5.56% 2.54%
Net Income Q/Q Growth		 -6.79% -20.91% 3.34% -4.25% 12.13% -10.30% 12.45% 18.95% -19.39% 5.03% 1.90%
EPS Q/Q Growth		 -212.50% 60.00% 0.00% 0.00% 10.00% -11.11% 10.00% 22.22% -14.29% 0.00% 12.50%
Operating Cash Flow Q/Q Growth		 -36.26% -17.27% 36.94% -81.52% 64.93% -213.27% 48.24% -0.53% 16.94% -107.97% 33.30%
Free Cash Flow Firm Q/Q Growth		 -75.10% 0.87% 9.30% -20.39% 51.57% -22.48% -2.32% 44.85% -59.94% -14.35% 0.25%
Invested Capital Q/Q Growth		 50.16% 58.99% -239.18% 91.79% -1,818.52% 47.68% -27.49% 10.56% -98.06% 70.92% -29.78%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 89.18% 91.16% 91.72% 92.29% 92.10% 94.89% 93.67% 93.60% 94.65% 95.18% 95.81%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -38.51% -43.02% -48.41% -55.24% -60.10% -62.61% -65.38% -62.15% -67.17% -68.07% -71.97%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -39.86% -44.62% -50.35% -57.70% -63.05% -65.93% -69.22% -66.05% -71.91% -73.34% -78.15%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -44.16% -49.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.14 -2.53 -2.43 -2.51 -2.21 -2.37 -2.10 -1.71 -2.01 -1.90 -1.85
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.19% -2.97% -3.00% -3.46% -3.19% -4.11% -3.66% -3.13% -4.04% -4.35% -4.67%
Return On Investment Capital (ROIC_SIMPLE)		 -9.14% -10.70% -10.75% -12.15% -11.72% -14.18% -14.10% -11.06% -14.43% -13.73% -14.01%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.05 -3.61 -3.47 -3.59 -3.16 -3.39 -3.00 -2.44 -2.88 -2.72 -2.65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.04 -3.60 -3.46 -3.59 -3.15 -3.63 -2.82 -2.44 -2.92 -2.66 -2.61
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.03 5.73 4.01 4.88 5.63 5.23 5.59 5.94 8.97 6.73 6.95
Price to Tangible Book Value (P/TBV)		 4.03 5.73 4.01 4.88 5.63 5.23 5.59 5.94 8.97 6.73 6.95
Price to Revenue (P/Rev)		 467.53 671.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 349.39 553.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.02 -1.04 -1.02 -1.04 -1.02 -1.04 -1.02 -1.07 -1.03 -1.04
Leverage Ratio		 1.08 1.06 1.07 1.09 1.11 1.10 1.10 1.12 1.15 1.12 1.13
Compound Leverage Factor		 0.97 0.97 0.98 1.01 1.03 1.04 1.03 1.05 1.09 1.06 1.08
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -4.13% -4.24% -4.61% -5.22% -5.88% -6.82% -7.80% -7.68% -8.68% -8.89% -9.46%
Common Equity to Total Capital		 104.13% 104.24% 104.61% 105.22% 105.88% 106.82% 107.80% 107.68% 108.68% 108.89% 109.46%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 15.58 35.75 19.20 14.79 9.95 7.95 6.15 7.24 16.83 21.03 13.07
Noncontrolling Interest Sharing Ratio		 -3.52% -3.72% -4.00% -4.45% -4.91% -5.31% -5.88% -6.27% -7.07% -7.76% -8.58%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.50 15.19 14.40 11.31 8.54 9.35 8.89 8.45 8.08 12.18 9.79
Quick Ratio		 11.89 14.57 13.95 10.56 8.04 8.63 8.27 7.76 7.71 11.49 9.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.15 -3.12 -2.83 -3.41 -1.65 -2.02 -2.07 -1.14 -1.83 -2.09 -2.08
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 1.33 0.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 274.62 467.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 274.62 467.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.47 -0.19 -0.66 -0.05 -1.04 -0.54 -0.69 -0.62 -1.22 -0.36 -0.46
Invested Capital Turnover		 -0.21 -0.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.01 0.60 0.41 0.90 -0.56 -0.35 -0.03 -0.56 -0.19 0.19 0.23
Enterprise Value (EV)		 73 116 70 84 92 75 73 81 120 86 86
Market Capitalization		 98 141 95 106 113 93 90 99 136 101 101
Book Value per Share		 $0.78 $0.78 $0.74 $0.68 $0.62 $0.55 $0.50 $0.52 $0.46 $0.45 $0.43
Tangible Book Value per Share		 $0.78 $0.78 $0.74 $0.68 $0.62 $0.55 $0.50 $0.52 $0.46 $0.45 $0.43
Total Capital		 23 24 23 21 19 17 15 15 14 14 13
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -24 -24 -23 -21 -20 -17 -16 -16 -15 -14 -14
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.52 -0.24 -0.71 -0.08 -1.06 -0.57 -0.72 -0.65 -1.25 -0.39 -0.50
Debt-free Net Working Capital (DFNWC)		 23 24 23 21 19 17 15 15 14 14 13
Net Working Capital (NWC)		 23 24 23 21 19 17 15 15 14 14 13
Net Nonoperating Expense (NNE)		 0.59 0.76 0.75 0.80 0.70 0.84 0.71 0.57 0.71 0.68 0.68
Net Nonoperating Obligations (NNO)		 -24 -24 -23 -21 -20 -17 -16 -16 -15 -14 -14
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.01 0.00 0.01 -0.24 0.18 -0.01 -0.04 0.06 0.03
Debt-free, Cash-free Net Working Capital to Revenue		 -245.71% -113.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 11,108.57% 11,218.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 11,108.57% 11,218.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.25) $0.10 ($0.10) ($0.10) ($0.09) ($0.10) ($0.09) ($0.07) ($0.08) ($0.08) ($0.07)
Adjusted Weighted Average Basic Shares Outstanding		 30.98M 31.45K 31.91M 32.05M 31.90M 32.20M 32.20M 32.48M 32.45M 33.24M 33.59M
Adjusted Diluted Earnings per Share		 ($0.25) $0.10 ($0.10) ($0.10) ($0.09) ($0.10) ($0.09) ($0.07) ($0.08) ($0.08) ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding		 30.98M 31.45K 31.91M 32.05M 31.90M 32.20M 32.20M 32.48M 32.45M 33.24M 33.59M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 31.70M 31.90M 32.01M 32.18M 32.20M 32.20M 32.21M 32.92M 33.38M 33.53M 34.02M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.14 -2.53 -2.43 -2.51 -2.21 -2.37 -2.10 -1.71 -2.01 -1.90 -1.85
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Anixa Biosciences (NASDAQ: ANIX) remains a pre-revenue biotech with a balance sheet that is still fairly liquid, but its latest quarterly results show continued operating losses and ongoing cash burn. Over the last several years, the company has consistently generated no revenue while funding research and overhead through its cash, investments, and periodic financing.

What stands out in the latest quarter (Q2 2026):

  • Cash, cash equivalents, and short-term investments totaled about $13.7 million, giving the company a meaningful liquidity cushion despite losses.
  • The company produced positive investing cash flow of $422,000 in Q2 2026, helped by selling more investments than it purchased during the quarter.
  • Financing activities provided $1.249 million of cash in Q2 2026, helping offset operating losses.
  • Basic and diluted share count in Q2 2026 were both 33.6 million, only modestly above the prior quarter, suggesting limited dilution in the period.
  • The company continues to hold very little debt, with total liabilities of only $1.64 million versus total assets of $14.87 million.
  • Interest and investment income of $111,000 helped reduce the quarterly pre-tax loss, though it was not enough to materially change the bottom line.
  • Research and development spending remains a core use of cash at $1.26 million in Q2 2026, consistent with a development-stage biotech.
  • ANIX posted a net loss of $2.54 million in Q2 2026, with no revenue to offset operating expenses.
  • Operating cash flow was negative $1.74 million in Q2 2026, showing the business is still consuming cash to fund operations.
  • Cash and equivalents declined from $1.55 million in Q1 2026 to $1.48 million in Q2 2026, while total current assets also edged lower quarter over quarter.

Longer-term trends:

ANIX has shown a fairly consistent pattern over the past four years: no revenue, recurring net losses, and reliance on investment income and financing to support operations. Quarterly operating losses have generally ranged between roughly $2.4 million and $3.6 million, which is typical for an early-stage biotech but still highlights the need for future funding or eventual commercialization success.

There are some signs of improvement in capital efficiency. Compared with earlier periods, the company has periodically kept cash burn somewhat contained, and its balance sheet remains debt-light. However, the business still has negative retained earnings of about $256.8 million, reflecting years of accumulated losses and underscoring that profitability is still far off.

Key investor takeaways:

  • ANIX has enough liquid resources to continue near-term operations.
  • Debt levels are minimal, which reduces balance sheet risk.
  • Investment income and financing have helped cushion operating losses.
  • The company remains pre-revenue and unprofitable.
  • Cash burn continues, so future dilution or additional capital raises remain possible.
  • The business is still highly dependent on pipeline progress rather than current commercial fundamentals.

Bottom line: Anixa Biosciences has a manageable balance sheet for now, but the stock remains a high-risk biotech story driven by clinical progress rather than financial performance. Investors should focus on whether the company can advance its programs while preserving enough cash to avoid near-term financing pressure.

07/27/26 10:16 PM ETAI Generated. May Contain Errors.

Anixa Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Anixa Biosciences' fiscal year ends in October. Their fiscal year 2025 ended on October 31, 2025.

Anixa Biosciences' net income appears to be on an upward trend, with a most recent value of -$11.03 million in 2025, rising from -$9.61 million in 2014. The previous period was -$12.70 million in 2024. Check out Anixa Biosciences' forecast to explore projected trends and price targets.

Anixa Biosciences' total operating income in 2025 was -$11.70 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.70 million

Over the last 10 years, Anixa Biosciences' total revenue changed from $3.67 million in 2014 to $0.00 in 2025, a change of -100.0%.

Anixa Biosciences' total liabilities were at $2.13 million at the end of 2025, a 21.2% decrease from 2024, and a 57.8% decrease since 2014.

In the past 10 years, Anixa Biosciences' cash and equivalents has ranged from $915 thousand in 2023 to $12.36 million in 2022, and is currently $1.24 million as of their latest financial filing in 2025.

Over the last 10 years, Anixa Biosciences' book value per share changed from 0.46 in 2014 to 0.46 in 2025, a change of 0.4%.


Related Companies

Financial statements for NASDAQ:ANIX last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel